Your browser doesn't support javascript.
loading
Inhibition of Melanoma Cell-Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis.
Schatton, Tobias; Itoh, Yuta; Martins, Christina; Rasbach, Erik; Singh, Praveen; Silva, Mariana; Mucciarone, Kyla; Heppt, Markus V; Geddes-Sweeney, Jenna; Stewart, Kate; Brandenburg, Anne; Liang, Jennifer; Dimitroff, Charles J; Mihm, Martin C; Landsberg, Jennifer; Schlapbach, Christoph; Lian, Christine G; Murphy, George F; Kupper, Thomas S; Ramsey, Matthew R; Barthel, Steven R.
Affiliation
  • Schatton T; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Itoh Y; Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Martins C; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Rasbach E; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Singh P; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Silva M; Department of Surgery, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
  • Mucciarone K; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Heppt MV; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Geddes-Sweeney J; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Stewart K; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Brandenburg A; Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University (FAU) Erlangen-Nuremberg, Erlangen, Germany.
  • Liang J; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Dimitroff CJ; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Mihm MC; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Landsberg J; Department of Dermatology and Allergology, University Hospital Bonn, Bonn, Germany.
  • Schlapbach C; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Lian CG; Department of Translational Medicine, Translational Glycobiology Institute at FIU, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida.
  • Murphy GF; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Kupper TS; Department of Dermatology and Allergology, University Hospital Bonn, Bonn, Germany.
  • Ramsey MR; Department of Dermatology, University of Bern, Bern, Switzerland.
  • Barthel SR; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Cancer Res ; 82(20): 3774-3784, 2022 10 17.
Article in En | MEDLINE | ID: mdl-35980306
ABSTRACT
T-cell immunoglobulin mucin family member 3 (Tim-3) is an immune checkpoint receptor that dampens effector functions and causes terminal exhaustion of cytotoxic T cells. Tim-3 inhibitors are under investigation in immuno-oncology (IO) trials, because blockade of T-cell-Tim-3 enhances antitumor immunity. Here, we identify an additional role for Tim-3 as a growth-suppressive receptor intrinsic to melanoma cells. Inhibition of melanoma cell-Tim-3 promoted tumor growth in both immunocompetent and immunocompromised mice, while melanoma-specific Tim-3 overexpression attenuated tumorigenesis. Ab-mediated Tim-3 blockade inhibited growth of immunogenic murine melanomas in T-cell-competent hosts, consistent with established antitumor effects of T-cell-Tim-3 inhibition. In contrast, Tim-3 Ab administration stimulated tumorigenesis of both highly and lesser immunogenic murine and human melanomas in T-cell-deficient mice, confirming growth-promoting effects of melanoma-Tim-3 antagonism. Melanoma-Tim-3 activation suppressed, while its blockade enhanced, phosphorylation of pro-proliferative downstream MAPK signaling mediators. Finally, pharmacologic MAPK inhibition reversed unwanted Tim-3 Ab-mediated tumorigenesis in T-cell-deficient mice and enhanced desired antitumor activity of Tim-3 interference in T-cell-competent hosts. These results identify melanoma-Tim-3 blockade as a mechanism that antagonizes T-cell-Tim-3-directed IO therapeutic efficacy. They further reveal MAPK targeting as a combination strategy for circumventing adverse consequences of unintended melanoma-Tim-3 inhibition.

SIGNIFICANCE:

Tim-3 is a growth-suppressive receptor intrinsic to melanoma cells, the blockade of which promotes MAPK-dependent tumorigenesis and thus counteracts antitumor activity of T-cell-directed Tim-3 inhibition.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hepatitis A Virus Cellular Receptor 2 / Melanoma Limits: Animals / Humans Language: En Journal: Cancer Res Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hepatitis A Virus Cellular Receptor 2 / Melanoma Limits: Animals / Humans Language: En Journal: Cancer Res Year: 2022 Document type: Article